Doing so allowed us to demonstrate that both GFAP and YKL-40 levels are not only elevated in patients on the AD continuum compared with CU, but also within the AD clinical spectrum, with higher levels seen in more advanced clinical stages. The gene discussed is GFAP; the disease is Alzheimer disease.